Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Casmara Cosmetics, S.A.
WARNING LETTER
•Casmara Cosmetics, S.A.•May 31, 2017

Casmara Cosmetics, S.A. – FDA Warning Letter, May 31, 2017

Record Details

The FDA inspected Casmara Cosmetics, S.A.'s drug manufacturing facility in Paterna, Spain, from May 29-31, 2017, identifying significant violations of current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211). Consequently, the firm's drug products are deemed adulterated under section 501(a)(2)(B) of the FD&C Act. The inspection revealed four primary deficiencies: 1) failure to conduct appropriate laboratory testing for identity and strength of active ingredients in drug products prior to release (21 CFR 211.165(a)); 2) failure to test incoming components, including active pharmaceutical ingredients, for identity and other quality attributes, relying instead on unqualified supplier certificates of analysis (21 CFR 211.84(d)(1) and (2)); 3) an inadequate stability testing program that lacked active ingredient testing, preventing the determination of appropriate storage conditions and expiration dates (21 CFR 211.166(a)); and 4) failure to establish written procedures for production and process control, including unvalidated manufacturing processes and insufficient batch records (21 CFR 211.100(a)). The firm's initial response was deemed insufficient. FDA requires a detailed written response within 15 working days outlining comprehensive corrective actions, including specific test methods, timelines for testing all in-date products, supplier validation procedures, risk assessments for products containing (b)(4) and those lacking stability data, and process validation plans. The FDA strongly recommended engaging a CGMP consultant. As a result of these violations, the firm was placed on Import Alert 66-40, and FDA may withhold approval of new applications or refuse admission of products into the U.S. The letter also noted labeling concerns for OTC drug products.

Company
Casmara Cosmetics, S.A.
Inspection date
May 31, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 91e8de43-7477-4af2-9a3d-bfd51b595366

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.165(a)21 CFR 211.84(d)(1)21 CFR 211.84(d)(2)21 CFR 211.166(a)21 CFR 211.100(a)21 CFR 211.34FD&C Act 501(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Casmara Cosmetics, S.A.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.